A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Trial Profile

A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Ifosfamide (Primary)
  • Indications Sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Planned number of patients added (36) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top